Early detection of prostate cancer is an important health care issue. The PSA test is a prostate cancer screening test administered by primary care physicians and urologists around the world. However, approximately 75% of prostate biopsies performed are negative for cancer, which calls out the need for a more specific test to help reduce unnecessary biopsies. In a patient with an elevated PSA test result in the 4-10 ng/mL range, the Prostate Health Index (phi) test is an option to determine the risk of prostate cancer and whether or not a biopsy is warranted.
The phi test utilizes a calculation that combines the results of three quantitative blood serum immunoassays (PSA, free PSA and p2PSA) into a single numerical result (the "phi score"). This score gives more accurate information about what an elevated PSA level might mean and the probability of finding prostate cancer with a biopsy. The p2PSA assay is specific to measuring [-2] proPSA. The [-2] proPSA biomarker is an isoform of free PSA that was identified as the most prostate cancer-specific form found in tumor extracts. 
THE PERCENTAGE OF PROSTATE-SPECIFIC ANTIGEN (PSA) ISOFORM [-2] PROPSA AND THE PROSTATE HEALTH INDEX IMPROVE THE DIAGNOSTIC ACCURACY FOR CLINICALLY RELEVANT PROSTATE CANCER AT INITIAL AND REPEAT

Key Points:
} A prospective multi-center study that assessed 769 men aged ≤ 65 years with a PSA concentration of 2.0-10.0 ng/mL scheduled for initial or repeat prostate biopsy. } The diagnostic accuracy of %p2PSA and phi for discrimination between significant and insignificant prostate cancer was evaluated. } phi was the best predictor of prostate cancer at initial and repeat biopsy with an ROC area under the curve (AUC) of 0.73. } %p2PSA and phi have a superior diagnostic performance for detecting prostate cancer in the PSA range of 2.0-10.0 ng/mL compared with total PSA and %free PSA at initial and repeat biopsy.
